Clinical Trials Results, Financial Results, and Upcoming Earnings Releases- Research Report on Teleflex, Oxygen Biotherapeutics, Novavax, Prana Biotechnology and Hanger Orthopedic PR Newswire NEW YORK, November 4, 2013 NEW YORK, November 4, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Analysts' Corner announced new research reports highlighting Teleflex Incorporated (NYSE: TFX), Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), Novavax, Inc. (NASDAQ: NVAX), Prana Biotechnology Ltd. (NASDAQ: PRAN) and Hanger Orthopedic Group Inc. (NYSE: HGR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Teleflex Incorporated Research Report On October 30, 2013, Teleflex Inc. (Teleflex) announced its Q3 FY 2013 (period ended September 29, 2013) financial results. The Company reported net revenues totaling $413.8 million, up 12.4% YoY. GAAP diluted EPS from continuing operations totaled $1.05 in Q3 FY 2013, compared to $0.58 in Q3 FY 2012. Benson Smith, Chairman, President and CEO at Teleflex, commented, "Teleflex delivered solid third quarter constant currency revenue growth and continued to successfully execute on our initiatives to expand both gross and operating margins. Our quarterly revenue performance was paced by continued strength in Critical Care, which was aided by the contribution from our acquisition of LMA International in 2012, an improvement in the average selling price of products and the continued introduction of new products to the marketplace. In addition, the third quarter results demonstrate the early benefit of our actions focused on cost control to improve operating leverage in the business." Teleflex stated that for full-year FY 2013, it anticipates constant currency revenue growth to be between 8.5% and 10% and adjusted diluted earnings per share in the range of $4.85 to $5.00. The Full Research Report on Teleflex Incorporated - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/9c7d_TFX] Oxygen Biotherapeutics, Inc. Research Report On October 30, 2013, Oxygen Biotherapeutics, Inc. (Oxygen Biotherapeutics) and Phyxius Pharma, Inc. announced that researchers at the Duke Clinical Research Institute have recently published findings of a meta-analysis of multiple clinical trials that evaluated the use of levosimendan in patients undergoing heart surgery. According to the Company, the results of the study showed that levosimendan was associated with reduced mortality (death) and other adverse outcomes including heart attacks during and after operation in patients with reduced heart functions undergoing heart surgery. Oxygen Biotherapeutics informed that the research was published in the Journal of Cardiothoracic and Vascular Anesthesia as an "in Press" online version of the publication that precedes the final publication. The Full Research Report on Oxygen Biotherapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/5700_OXBT] Novavax, Inc. Research Report On October 30, 2013, Novavax Inc. (Novavax) announced the schedule of its earnings release and conference call. Novavax informed that it will host a conference call and live webcast for reporting its Q3 2013 financial results on Thursday, November 7, 2013 at 4:30 p.m. ET. The Company added that the webcast and its replay can be accessed via its website under Investor Info/Events section. The Full Research Report on Novavax, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/bc35_NVAX] Prana Biotechnology Ltd. Research Report On October 31, 2013, Prana Biotechnology (Prana) announced the publication of an article in the peer reviewed journal Aging Cell, titled "A Novel Approach To Rapidly Prevent Age-Related Cognitive Decline", showing the effects of its drug, PBT2, on neurogenesis and in reversing the memory and learning losses associated with the aging process, in normal (i.e. non transgenic) old mice. Dr. Rudy Tanzi, Professor of Neurology at Harvard Medical School, Vice Chair of Neurology at Massachusetts General Hospital, and Prana's Chief Scientific Advisor, commented, "It is very exciting to discover that PBT2 not only helps clear amyloid from the brain, but is promoting the birth of new nerve cells in a part of the brain that is particularly affected by Alzheimer's disease, the hippocampus. This now adds to the predicted beneficial properties of PBT2 for the treatment and prevention of Alzheimer's disease." The Full Research Report on Prana Biotechnology Ltd. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/9f3a_PRAN] Hanger Orthopedic Group Inc. Research Report On October 29, 2013, Hanger, Inc. (Hanger) announced its Q3 2013 financial results with net sales totaling $271.1 million, up 11.8% YoY. Adjusted diluted EPS of the Company grew 24.0% YoY to $0.62 during the quarter. Hanger reported income from operations of $39.9 million in Q3 2013, compared to $35.4 million in Q3 2012. Commenting on the results, Vinit K. Asar, President and CEO of Hanger, stated, "We are pleased with our revenue and earnings momentum in the third quarter. We delivered strong same center sales growth of 3.8% in our Patient Care segment and started to gain traction from our materials management initiatives." The Company stated that for full-year 2013 it expects its net sales to a range between $1.045 billion and $1.055 billion, representing 7% and 8% YoY growth. The Full Research Report on Hanger Orthopedic Group Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/0e96_HGR] EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. http://www.analystscorner.com SOURCE Analysts' Corner Contact: Joe Thomas; +1-310-496-8071 (North America)
Clinical Trials Results, Financial Results, and Upcoming Earnings Releases- Research Report on Teleflex, Oxygen Biotherapeutics,
Press spacebar to pause and continue. Press esc to stop.